24 June 2024 - As the government will likely reflect innovative new drug values on its reimbursement criteria this year, expectations are rising for the coverage of triple-negative breast cancer drug Troldelvy (sacituzumab govitecan), which has garnered 100,000 petitions.

In April, the Ministry of Health and Welfare announced its policy to flexibly apply cost effectiveness evaluation acceptance to drugs that meet the criteria for innovation under the Second Comprehensive National Health Insurance Plan’s 2024 Implementation Program. To this end, the ministry plans to finalise the new drug’s innovativeness criteria and revise related regulations in the first half of this year.

Read Korean Biomedical Review article